Northern Trust Corp Purchases 354,871 Shares of Moderna, Inc. (NASDAQ:MRNA)

Northern Trust Corp grew its position in Moderna, Inc. (NASDAQ:MRNA) by 13.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,959,054 shares of the company’s stock after purchasing an additional 354,871 shares during the period. Northern Trust Corp owned about 0.77% of Moderna worth $123,037,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Allworth Financial LP lifted its holdings in Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after acquiring an additional 281 shares in the last quarter. Howard Capital Management Inc. lifted its holdings in shares of Moderna by 3.1% during the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock valued at $416,000 after purchasing an additional 297 shares in the last quarter. Commonwealth Equity Services LLC grew its position in shares of Moderna by 0.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company’s stock valued at $3,099,000 after purchasing an additional 345 shares during the period. Larson Financial Group LLC increased its stake in Moderna by 39.1% during the 4th quarter. Larson Financial Group LLC now owns 1,266 shares of the company’s stock worth $53,000 after purchasing an additional 356 shares in the last quarter. Finally, New Insight Wealth Advisors raised its holdings in Moderna by 4.4% during the 4th quarter. New Insight Wealth Advisors now owns 8,545 shares of the company’s stock worth $355,000 after buying an additional 358 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna Stock Performance

NASDAQ MRNA opened at $27.61 on Friday. The stock has a market cap of $10.67 billion, a PE ratio of -2.98 and a beta of 2.23. The firm has a 50-day moving average of $29.52 and a 200-day moving average of $37.60. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.92) by $0.40. The company had revenue of $108.00 million during the quarter, compared to analysts’ expectations of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The business’s revenue was down 35.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($3.07) earnings per share. As a group, analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MRNA has been the subject of several research reports. JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Friday, March 21st. Barclays lowered their target price on Moderna from $45.00 to $40.00 and set an “equal weight” rating for the company in a report on Friday. Berenberg Bank upped their price objective on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Bank of America dropped their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada reduced their price target on Moderna from $32.00 to $28.00 and set a “sector perform” rating for the company in a research report on Friday. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $56.55.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.